<DOC>
	<DOCNO>NCT00871663</DOCNO>
	<brief_summary>The study evaluate safety , tolerability , maximum administer dose , dose limit toxicity SCH 727965 administer intravenous infusion Days 1 , 8 15 28 day cycle participant solid tumor , non Hodgkins lymphoma , multiple myeloma chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Phase 1 Weekly Dosing SCH 727965 Patients With Advanced Cancer ( Study P04629AM6 )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Age &gt; =18 year , either sex , race . Eastern Cooperative Oncology Group performance status 0 , 1 , 2 . There must know standard therapy , disease must refractory standard therapy Adequate hematologic , renal , hepatic organ function laboratory parameter For advanced solid tumor , nonHodgkin 's lymphoma , multiple myeloma : Participants must histologically prove solid tumor , nonHodgkin 's lymphoma , multiple myeloma . Evaluable malignancy must present computed tomography magnetic resonance imaging , obtain within 4 week prior start treatment SCH 727965 . Subjects multiple myeloma must measurable disease define : Serum monoclonal protein great 0.5 g/dL urine light chain excretion great 0.2 g/24hour obtain within 4 week prior start treatment . Participants low M protein value nonsecretory myeloma eligible measurable disease establish within 4 week prior start treatment , : serum free light chain ratio great 5 time normal ratio limit ; and/or measurable soft tissue plasmacytoma great 2 cm , either physical examination and/or applicable radiograph ; and/or bone marrow involvement great 30 % . For Bcell chronic lymphocytic leukemia ( BCLL ) : Diagnosis BCLL accord National Cancer Institute Working Group ( NCIWG ) criteria histological diagnosis small lymphocytic lymphoma . Disease must evaluable accord NCIWG response criterion . Symptomatic brain metastasis primary central nervous system malignancy . Previous radiation therapy &gt; 25 % total bone marrow . Previous treatment SCH 727965 . Known HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>